Oyster Point Pharma Inc (OYST) USD0.001

- Add to watchlist
- This stock can be held in a




Business summary
Oyster Point Pharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate is OC-01 (varenicline), a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity, and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
Contact details
Important dates
General stock information
- Short code:
- OYST
- ISIN:
- US69242L1061
- Market cap:
- $529.59 million
- Shares in issue:
- 25.91 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.